Invectys reports in vivo efficacy of its pan anti-tumor...
Invectys reports in vivo efficacy of its pan anti-tumor anti-HLA-G CAR-T cells These results open new perspectives in oncology for targeting cancer through HLA-G,…
Read more
Invectys reports in vivo efficacy of its pan anti-tumor anti-HLA-G CAR-T cells These results open new perspectives in oncology for targeting cancer through HLA-G,…
Invectys publishes positive clinical results for its INVAC-1 Phase I Study in Clinical Cancer Research With an extended Phase I and a new delivery method…
Invectys : lutter contre toutes les formes de cancers Avec 382 000 nouveaux cas et 157 400 décès par an, le cancer demeure une priorité absolue en matière de…
The main product of Invectys is a DNA vaccine targeting Telomerase…
The telomerase enzyme functions as part of a large ensemble of proteins and RNA called the telomerase ribonucleoprotein complex.…
Monoclonal antibodies targeting checkpoint inhibitors are hugely important immunotherapy molecules for the treatment cancers…